MEDFORD, NY--(Marketwire - November 20, 2008) - Chembio Diagnostics, Inc. (OTCBB: CEMI) (“Chembio” or the “Company”) has completed the first shipment of products based upon its patented Dual Path Platform or DPP® product technology. This shipment represents a significant milestone for the Company’s strategy to develop OEM and branded products utilizing its Dual Path Platform technology and its development, regulatory and manufacturing capabilities.
